Oxygen Atom Of The Saccharide Radical Is Bonded To A Cyclohexyl Radical (e.g., Kasugamycin, Etc.) Patents (Class 435/79)
-
Patent number: 5919615Abstract: The present invention provides papillomavirus polypeptides and antibodies against said polypeptides. The peptides and antibodies of the present invention are particularly useful for in the prevention, diagnosis, and treatment of infections caused by distinct papillomaviruses. These papillomaviruses are linked to distinct infectious states. The polypeptides of the present invention are derived from L2 genes of different papillomaviruses (or from a portion of said genes). The present invention further provides kits containing one or more antibodies according to the present invention, and a method for the detection and identification of papillomaviruses in biological samples by immunological reaction with said antibodies. The diagnostic kits of the present invention are suitable for diagnosis of the specific infection affecting the donor subject of the biological sample, or infections to which the subject risks being exposed.Type: GrantFiled: June 6, 1995Date of Patent: July 6, 1999Assignee: Institut Pasteur and Institut National de la Sante et de la Recherche MedicaleInventors: Carol Ann Komly, Odile Croissant, Francoise Breitburd
-
Patent number: 5916746Abstract: This invention relates to an improved method for detecting and quantifying the presence of a target molecule, such as an antigen, an antibody or a polynucleotide, in a sample which method uses alkaline phosphatase as the reporter enzyme and the reduction of a tetrazolium salt to a formazan as part of the detection/signaling system.Type: GrantFiled: May 9, 1996Date of Patent: June 29, 1999Assignee: Kirkegaard & Perry Laboratories, Inc.Inventors: Carrington S. Cobbs, Thomas M. Woerner
-
Patent number: 5914239Abstract: A 134 kDa, calcium-independent, chitin-binding lectin called chitovibrin is secreted by marine bacteria of the genus Vibrio. The secretion of chitovibrin is inducible by chitin or chitin-oligomers. Chitovibrin shows no apparent enzymatic activity, but has a strong affinity for chitin and for chito-oligomers dp9 and larger. The protein has an isoelectric pH of 3.6, shows thermal tolerance, binds chitin with an optimum at pH 6 and is active in 0-4 M NaCl. Chitovibrin is useful as a stain for fungi and other chitin-containing organisms. Chitovibrin may be used to detect the presence of chitin, particularly in diagnosing fungal infections in humans, animals, and plant materials. Fungal infections are a particular problem in immunocompromised hosts such as AIDS patients and bone marrow transplant patients, because they can cause opportunistic infections. The chitovibrin diagnostic method allows the convenient, broad spectrum diagnosis of fungal infections in tissue samples or in body fluids.Type: GrantFiled: November 8, 1996Date of Patent: June 22, 1999Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventor: Roger A. Laine
-
Patent number: 5912136Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Kits and methods are also provided for detecting, measuring and immunopurifying human interleukin-4.Type: GrantFiled: December 12, 1994Date of Patent: June 15, 1999Assignee: Schering CorporationInventors: John S. Abrams, Isabelle Chretien, Frank D. Lee
-
Patent number: 5910410Abstract: A method for detecting the presence of a target nucleic acid species having first, second and third target sequences. In the present invention, a solution to be tested is brought into contact with a solid support having a probe nucleic acid species attached thereto, the probe nucleic acid sequence comprising a sequence that is complementary to the first target sequence. A dye solution is then brought into contact with the solid support. The dye solution includes a first dye attachment nucleic acid sequence coupled to a first dye and a second dye attachment nucleic acid sequence coupled to a second dye. The first dye attachment nucleic acid sequence is complementary to the second target sequence and the second dye attachment nucleic acid sequence is complementary to the third target sequence.Type: GrantFiled: September 6, 1996Date of Patent: June 8, 1999Assignee: Hewlett-Packard CompanyInventors: Kay Lichtenwalter, Calvin B. Ward
-
Patent number: 5910419Abstract: A method for conducting a screening test series for indications of use of drugs of abuse is set forth including enzyme linked immunosorbant assay (ELISA) and radioimmunoassay (RAI) for various analytes extracted from hair samples is set forth. The collected hair sample is divided into portions. One portion is screened cannabinoids using ELISA. Another portion is screened for opiates, PCP, amphetamines and methamphetamines using a combination of RIA or ELISA. Results deemed positive from the screening series are confirmed positive or negative by known techniques such as gas chromatography-mass spectrometry. Those deemed negative are so reportable without the necessity of the expensive confirmatory procedures.Type: GrantFiled: May 6, 1997Date of Patent: June 8, 1999Inventors: Ted Donald Johnson, W. Craig Brown, Raymond C. Kelly
-
Patent number: 5910418Abstract: Antibodies and assays employing them are taught which are useful for detecting the bulk of mutations which occur in the APC gene in familial adenomatous polyposis. The antibodies are specific for epitopes in the amino terminal or carboxy terminal portion of the protein. A variety of immunoassay formats are described which are all based on the observation that the bulk of the APC mutations which occur in familial adenomatous polyposis and sporadic colorectal carcinomas result in truncated APC proteins. Generally, either the size of APC proteins is determined or the relative binding of amino terminal-binding antibodies to carboxy terminal-binding antibodies is determined.Type: GrantFiled: January 9, 1995Date of Patent: June 8, 1999Assignee: The Johns Hopkins UniversityInventors: David E. Hill, Karen A. Johnson, Kenneth W. Kinzler, Bert Vogelstein
-
Patent number: 5902727Abstract: A method for localizing and quantitating a target substance in a biological sample is disclosed. The method utilizes an enzyme-linked probe that binds to the target substance and generates a depositable chromogenic or fluorogenic substance which detects position and a soluble chromogenic or fluorogenic substance which allows quantitation in the medium bathing the sample.Type: GrantFiled: September 4, 1996Date of Patent: May 11, 1999Assignee: Washington UniversityInventors: Kevin A. Roth, Robinna Lorenz
-
Patent number: 5895819Abstract: An enzyme substrate is disclosed which comprises a phosphoric ester and an organic acid or a salt thereof having a zinc chelating stability factor constant (log K) of from 8 to 14 in an aqueous solution having an ionic strength of 0.1 at 20 to 25.degree. C. A reagent kit for an enzyme activity assay, a reagent kit for an immunoassay, a method for stabilizing a phosphoric ester, a method for producing a stabilized phosphoric ester.Type: GrantFiled: June 24, 1997Date of Patent: April 20, 1999Assignee: Tosoh CorporationInventor: Norio Hagi
-
Patent number: 5895750Abstract: A biotin-antibiotin immunoassay comprises coating a solid phase with a ligand-specific binding material, reacting the solid phase with a test sample, reacting the solid phase with the biotin-labeled form of the ligand-specific binding material and antibiotin labeled with a suitable marker. The marker is then measured to detect the amount of ligand present in the test sample.Type: GrantFiled: May 3, 1995Date of Patent: April 20, 1999Assignee: Abbott LaboratoriesInventors: Isa K. Mushahwar, Richard H. Decker, Karen V. Stuckmann
-
Patent number: 5895746Abstract: Aminoterminal propeptide of type I procollagen exists in serum in two forms: classical type I procollagen which is a heterotrimer containing two pro .alpha.1-chains and one pro .alpha.2-chain of type I procollagen, and an .alpha.1-homotrimer type I procollagen containing three identical pro .alpha.1-chains. These intact, trimeric aminoterminal propeptides may be isolated without the use of proteolytic enzymes and the resultant propeptides may be used to prepare antibodies specific for the intact trimeric propeptide, having no affinity for the monomeric form of the propeptide. Such antibodies are useful in methods of assaying intact trimeric aminoterminal propeptide of type I procollagen in serum, without false information resulting from inadvertent assay of the monomeric form of the propeptide.Type: GrantFiled: June 7, 1995Date of Patent: April 20, 1999Assignee: Orion-Yhtyma OyInventors: Juha Risteli, Leila Risteli, Jukka Melkko, Saila Kauppila
-
Patent number: 5894061Abstract: The diffusion through a membrane assaying apparatus and method facilitates rapid detection of small or larger molecular weight substances such as hazardous wastes, toxic chemicals or the like by using a semipermeable membrane having a predetermined molecular weight cutoff. The semipermeable membrane is provided as part of a container having a removable barrier which facilitates control of diffusion through the membrane. The assaying method includes the use of a reaction mechanism for detection of a predetermined substance. The reaction mechanism includes one or more reagents which are designed to either react or compete for a substance for which assaying is being performed. By selecting the proper reagents and molecular weight cutoff of the semipermeable membrane, the presence or absence of a reaction such as a color change or production of vapor provides indication whether the substance being assaying for is present in the test sample.Type: GrantFiled: January 29, 1996Date of Patent: April 13, 1999Inventor: Cynthia A. Ladouceur
-
Patent number: 5891649Abstract: The present invention is an apparatus and a method of detecting a chemical released by perspiration, typically through sweat and broadcasting the detection to a receiver. The chemical may be a drug of abuse. The device which is attached to the skin of a subject contains labeled antibodies or label containing microspheres attached to antibodies. The labeled antibodies are bound to solid phase drug via antigen-antibody interaction. These labeled antibodies are displaced from the solid phase support to which they are bound by free drug molecules in the perspiration. These labeled antibodies then migrate through a spacer layer and are trapped by a layer containing a suitable selective binding material. The label is illuminated or excited by a light source and detected by a photodetector. The signal can be recorded, or transmitted to a remote radio monitor.Type: GrantFiled: December 19, 1996Date of Patent: April 6, 1999Assignee: California Institute of TechnologyInventors: David A. Kidwell, Gil F. Richards, Roger G. Kern, Frederick W. Mintz
-
Patent number: 5891722Abstract: Antibodies having binding affinity for free IGFBP-1, biological compositions including antibodies having binding affinity for free IGFBP-1, kits for detecting free IGFBP-1 using the antibodies, and cell lines for producing the antibodies are provided. Also provided are devices and methods for detecting free IGFBP-1 and a rupture in a fetal membrane based on the presence of amniotic fluid in a vaginal secretion, as indicated by the presence of free IGFBP-1 in the vaginal secretion. The antibodies that are provided may be characterized by their ability to selectively recognize those IGFBP-1 molecules which are free of IGF-1 and IGF-2, i.e., antibodies which have a binding affinity for free IGFBP-1 that is greater than a binding affinity of the antibody to bound IGFBP-1. These antibodies may also be characterized by their competition with IGF-1 and IGF-2 for binding to IGFBP-1.Type: GrantFiled: October 28, 1996Date of Patent: April 6, 1999Assignee: California Research LLCInventors: Boris Fuks, Marina Boltovskaya, Alexander Konstantinov, Svetlana Nazimova, Nelli Starosvetskaya, Alexander Stepanov, Evgeny Zaraisky
-
Patent number: 5891628Abstract: The present invention relates to the identification of the autosomal dominant polycystic kidney disease (PKD) gene and high throughput assays to identify compounds that interfere with PKD activity. Interfering compounds that inhibit the expression, synthesis and/or bioactivity of the PKD gene product can be used therapeutically to treat polycystic kidney disease.Type: GrantFiled: June 2, 1995Date of Patent: April 6, 1999Assignees: Brigham and Women's Hospital, Millenium PharmaceuticalsInventors: Stephen Reeders, Michael Schneider, Maria Alexandra Glucksmann
-
Patent number: 5889158Abstract: This invention discloses the identification and characterization of a novel human retrovirus, originally designated lymphadenopathy-associated virus type II, or LAV-II, and subsequently redesignated the human immunodeficiency virus type 2, or HIV-2. This virus was isolated from West African AIDS patients and propagated on immortalized lymphocytic cell lines or donor peripheral blood mononuclear cells (PBMCs). Immunological and nucleic acid hybridization studies demonstrated that HIV-2 differs significantly from HIV-1, the aetiological agent of AIDS. Additional biochemical characterization identified viral antigens having molecular weights of 16, 26, 36, and 130-140 kDa, as determined by SDS-PAGE. These proteins were subsequently designated p16, p26, gp36, and gp130-140, respectively. These antigens can be employed, inter alia, in the generation of both polyclonal and monoclonal antibodies, which should prove useful in diagnostic and viral antigen purification applications.Type: GrantFiled: June 6, 1995Date of Patent: March 30, 1999Assignee: Institut PasteurInventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
-
Patent number: 5888744Abstract: Aminoglycosides such as aminoglycoside antibiotics are detected and separated by non-immunoaffinity binding to an immobilized binding protein which is preferably lysozyme or .alpha.-lactalbumin. Aminoglycosides are detected in a biological sample such as milk or a fermentation broth by contacting the sample with the binding protein immobilized on a solid carrier such as particles of carboxylated latex to bind the aminoglycosides to the binding protein, adding a label that binds to the aminoglycosides and measuring the label. In another embodiment, the binding protein containing bound aminoglycosides is separated from the sample, the aminoglycosides are removed from the binding protein, a label is added to the aminoglycosides and the label is measured. Aminoglycosides are removed from a sample by passing the sample through a bioreactor containing the binding protein immobilized on a solid carrier to bind the aminoglycosides to the binding protein and recovering the sample free of aminoglycosides.Type: GrantFiled: August 24, 1995Date of Patent: March 30, 1999Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Naomi F. Campbell, Marjorie B. Medina
-
Patent number: 5888746Abstract: A method for diagnosis or prognosis of a cancer is disclosed. The method comprises (i) detecting in a first biological sample protein tyrosine phosphate .alpha. (PTP.alpha.) or PTP.alpha. nucleic acid, and (ii) comparing the level of PTP.alpha. or PTP.alpha. nucleic acid in the first sample with the level in a second biological sample known to be from normal tissue. Any overexpression of PTP.alpha. or PTP.alpha. nucleic acid in the first sample compared to the second sample is indicative that the first sample is from a cancerous tissue.Type: GrantFiled: March 10, 1997Date of Patent: March 30, 1999Assignee: Institute of Molecular and Cell BiologyInventors: Karim Tabiti, Catherine Jane Pallen
-
Patent number: 5882935Abstract: An analysis element for analyzing both amounts of glycated hemoglobin and total hemoglobin in an aqueous liquid sample to determine glycated hemoglobin content ratio in the sample. The element comprises a substrate layer for receiving a reaction mixture after the completion of an immunological reaction between the glycated hemoglobin in the sample and an enzyme-labelled antibody against the glycated hemoglobin, and a reagent layer. The substrate layer contains a non-diffusible substrate which forms a diffusible material in the presence of the enzyme of the enzyme-labelled antibody, the activity of the enzyme being effected relative to the steric hindrance due to the immunological reaction. The reagent layer contains a reagent composition for reacting with the diffusible material to form a dye detectable colorimetrically in a wavelength range which is not effected by an absorption spectrum of the hemoglobin.Type: GrantFiled: October 17, 1995Date of Patent: March 16, 1999Assignee: Fuji Photo Film Co., Ltd.Inventors: Kikuo Hirai, Hiroshi Shinoki, Masashi Ogawa, Yoshihiko Makino
-
Patent number: 5879897Abstract: Disclosed are methods of detecting a gastric reflux in the esophagus or in the throat of a subject. The basis of the method is the detection of the presence of pepsin or pepsinogen at higher than normal levels. Detection is preferably by an immunoassay technique.Type: GrantFiled: September 23, 1996Date of Patent: March 9, 1999Assignee: Wake Forest UniversityInventor: James Koufman
-
Patent number: 5879881Abstract: A solid phase system for use in ligand-receptor assays, particularly immunoassays using monoclonal antibodies, is disclosed. The solid phase system comprises a porous matrix in which microspheres, bound with a receptor capable of capturing a target ligand, are entrapped. Preferably, the microspheres are entrapped within a discrete zone or zones of the porous matrix.Type: GrantFiled: December 7, 1993Date of Patent: March 9, 1999Assignee: Hybritech, IncorporatedInventor: Albert S. Rubenstein
-
Patent number: 5879951Abstract: An assay device for the performance of assays for analytes, particularly those of biological interest, provides for improved efficiency and sensitivity by reducing background. The assay device performs an immunochromatographic assay and also provides a wash to remove unbound labeled specific binding partner and thereby reduce the background. Assay devices according to the present invention can use either a directly visible label such as a metal sol label or an enzyme label. One embodiment of assay devices according to the present invention is particularly suitable for assay of analytes in whole blood samples. The present invention also encompasses test kits and methods of use of the assay devices.Type: GrantFiled: January 29, 1997Date of Patent: March 9, 1999Assignee: SmithKline Diagnostics, inc.Inventor: Vincent A. Sy
-
Patent number: 5876946Abstract: A homogeneous high throughput assay is described which screens compounds for enzyme inhibition, or receptor or other target binding. Inhibition (or binding) by the library compounds causes a change in the amount of an optically detectable label that is bound to suspendable cells or solid supports. The amounts of label bound to individual cells or solid supports are microscopically determined, and compared with the amount of label that is not bound to individual cells or solid supports. The degree of inhibition or binding is determined using this data. Confocal microscopy, and subsequent data analysis, allow the assay to be carried out without any separation step, and provide for high throughput screening of very small assay volumes using very small amounts of test compound.Type: GrantFiled: June 3, 1997Date of Patent: March 2, 1999Assignee: Pharmacopeia, Inc.Inventors: Jonathan J. Burbaum, Thomas D.Y. Chung, Gregory L. Kirk, James Inglese, Daniel Chelsky
-
Patent number: 5876948Abstract: Method for treatment of a disease in a patient characterized by accumulation of .beta.-amyloid. The method includes identifying a patient potentially suffering from such a disease and contacting a neuron of the patient with a therapeutically effective amount of a tachykinin agonist. Methods for screening for compounds useful for treating such a disease are also disclosed.Type: GrantFiled: July 29, 1991Date of Patent: March 2, 1999Assignee: The Children's Medical Center CorporationInventor: Bruce A. Yankner
-
Patent number: 5877029Abstract: Antibodies having binding affinity for free IGFBP-1, biological compositions including antibodies having binding affinity for free IGFBP-1, kits for detecting free IGFBP-1 using the antibodies, and cell lines for producing the antibodies are provided. Also provided are devices and methods for detecting free IGFBP-1 and a rupture in a fetal membrane based on the presence of amniotic fluid in a vaginal secretion, as indicated by the presence of free IGFBP-1 in the vaginal secretion. The antibodies that are provided may be characterized by their ability to selectively recognize those IGFBP-1 molecules which are free of IGF-1 and IGF-2, i.e., antibodies which have a binding affinity for free IGFBP-1 that is greater than a binding affinity of the antibody to bound IGFBP-1. These antibodies may also be characterized by their competition with IGF-1 and IGF-2 for binding to IGFBP-1.Type: GrantFiled: October 28, 1996Date of Patent: March 2, 1999Assignee: California Research LLCInventors: Boris Fuks, Marina Boltovskaya, Alexander Konstantinov, Svetlana Nazimova, Nelli Starosvetskaya, Alexander Stepanov, Evgeny Zaraisky
-
Patent number: 5876924Abstract: An improved method allowing for rapid sensitive and standardized detection of a target nucleic acid from a pathogenic microorganism or virus or normal or abnormal gene in a sample is provided. The method involves hybridizing a target nucleic acid to several non-overlapping oligonucleotide probes that hybridize to adjacent regions in the target nucleic acid, the probes being referred to capture/amplification probes and amplification probes, respectively, in the presence of paramagnetic beads coated with a ligand binding moiety. Through the binding of a ligand attached to one end of the capture/amplification probe and the specific hybridization of portions of the probes to adjacent sequences in the target nucleic acid, a complex comprising the target nucleic acid, the probes and the paramagnetic beads is formed. The probes may then ligated together to form a contiguous ligated amplification sequence bound to the beads, which complex may be denatured to remove the target nucleic acid and unligated probes.Type: GrantFiled: July 31, 1996Date of Patent: March 2, 1999Assignee: Mount Sinai School of MedicineInventors: David Y. Zhang, Margaret Brandwein
-
Patent number: 5874277Abstract: This invention relates to a novel calpain having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a pharmaceutical composition comprising the DNA, an antibody against the protein, a method for screening for a compound which activates or inhibits a proteolytic activity of the protein, a kit for screening for the compound, and a compound which activates or inhibits a proteolytic activity of the protein which is identified by the screening method or the kit. The DNA coding for the protein of the present invention can be used as a therapeutic and prophylactic composition for a variety of diseases including tumor, cerebral apoplexy, cerebral infarction, subarachnoid hemorrhage, Alzheimer's disease, myodystrophy, cataract, ischemic heart disease, atherosclerosis, arthritis, and collagen disease.Type: GrantFiled: April 4, 1997Date of Patent: February 23, 1999Assignee: Takeda Chemical Industries, LtdInventors: Yasushi Shintani, Kazunori Nishi, Tomohiro Kawamoto
-
Patent number: 5874228Abstract: The invention relates to novel purified human immunoglobulin E binding factors (IgE-BFs), its individual optionally glycosylated proteins, and fragments thereof, processes for the purification of IgE-BFs, novel monoclonal antibodies to lymphocyte cellular receptors for IgE (Fc.sub..epsilon. R) crossreacting with IgE-BFs, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, processes for the preparation of said hybridoma cell lines, the use of the monoclonal antibodies and their derivatives for the qualitative and quantitative determination of IgE-BFs, test kits containing the monoclonal antibodies and/or their derivatives, the use of the monoclonal antibodies for the purification of IgE-BFs, the use of purified IgE-BFs, its individual optionally glycosylated proteins and/or fragments thereof for the prevention and/or treatment of allergy, and to pharmaceutical preparations containing them.Type: GrantFiled: February 27, 1997Date of Patent: February 23, 1999Assignee: Novartis AGInventor: Guy Delespesse
-
Patent number: 5874226Abstract: An antibody targeted to an antigen is brought into contact with a body component in situ. The resulting antibody/antigen complex is labeled and may be amplified. The label is then detected either in situ or ex situ.Type: GrantFiled: May 22, 1995Date of Patent: February 23, 1999Assignee: H. Lee BrowneInventors: Fusun N. Zeytinoglu, Franz B. Thiebaut
-
Patent number: 5871939Abstract: An isolated immunoreactive molecule (IRM) capable of binding to a target molecule from at least one species or sub-species of the insect but not to at least one other species or sub-species of insect and a method of identifying one or more insect species or subspecies and kits therefor. The invention is particularly useful for distinguishing between Lepidopterans such as Helicoverpa armigera and H. punctigera.Type: GrantFiled: January 25, 1994Date of Patent: February 16, 1999Assignee: Commonwealth Scientific and Industrial Research OrganizationInventors: Stephen Charles Trowell, Kim Astrid Garsia, Amanda Susan Hill, Gabriele Annierose Lang, John Howard Skerritt
-
Patent number: 5869232Abstract: An antigen/antibody specificity exchanger is disclosed. It comprises: A) an amino-acid sequence corresponding to an amino-acid sequence of an antibody which specifically binds to a certain antigen, including hapten, B) linked by a link to C) an amino-acid sequence to which a certain antibody binds. Also, a diagnostic reagent comprising an antigen/antibody specificity exchanger according to the invention is disclosed. Said reagent may be e.g. used instead of antisera or monoclonal antibodies in in vitro testing systems, such as immunological tests. Further, a method of treating a disease or disorder caused by a known antigen in an individual in need of an increased number of antigen-specific antibodies is disclosed. In the method a tailor-made antigen/antibody specificity exchanger of the invention is issued. Said method may be e.g. used to redirect a patient's antibodies against poliovirus to fight HIV infection in said patient.Type: GrantFiled: December 27, 1996Date of Patent: February 9, 1999Assignee: Tripep ABInventor: Matti Sallberg
-
Patent number: 5869272Abstract: Method for the determination of chlamydial or gram negative bacterial antigen comprising contacting a sample potentially containing extracted antigen with an optically active surface comprising an attachment layer, and a layer of non-specific protein.Type: GrantFiled: May 31, 1995Date of Patent: February 9, 1999Assignee: Biostar, Inc.Inventors: Gregory R. Bogart, Garret R. Moddel, Diana M. Maul, Jeffrey B. Etter, Mark Crosby
-
Patent number: 5866347Abstract: A method of identifying individuals who have, or who are at risk of developing, autoimmune neuropsychiatric disorders is disclosed. The invented method relies on detection of the B lymphocyte antigen, D8/17. The invented method can conveniently be carried out as a simple blood test.Type: GrantFiled: April 8, 1997Date of Patent: February 2, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Susan E. Swedo, Henrietta L. Leonard, John B. Zabriskie
-
Patent number: 5863743Abstract: Disclosed is a method for aiding in the diagnosis of merosin deficiency-type congenital muscular dystrophy (CMD). The method is based on the discovery of a previously unidentified form of CMD which is characterized by a substantial reduction in the levels of merosin in skeletal muscle tissue containing normal levels of dystrophin and dystrophin-associated proteins.Type: GrantFiled: August 12, 1994Date of Patent: January 26, 1999Assignee: University of Iowa Research FoundationInventors: Kevin P. Campbell, Yoshihide Sunada, Fernando M. S. Tome, Michel Fardeau
-
Patent number: 5863742Abstract: A method of inhibiting proteolytic degradation of a thermally-stable intracellular protein is described. The method involves adding 1 or more denaturing agents to a sample which contains the protease and the protein of interest and heating the resulting solution at a temperature and for period of time sufficient to denature the protease. The method optionally includes a step for lysing the cell if the protein of interest is contained in a cell in order to release said protein. Additionally, a method of determining Mx protein induced by interferon in a blood sample is described. The method involves adding to a blood sample a lysing agent, a denaturing agent, and a detergent selected to solubilize Mx protein. The sample containing Mx protein is then heated at a temperature of from about 50.degree. C. to about 60.degree. C. for a period of time of from about 1 minute to about 30 minutes, and the Mx protein in the solution then is determined.Type: GrantFiled: March 10, 1994Date of Patent: January 26, 1999Assignee: Chiron Diagnostics CorporationInventors: Se-Kyung Oh, Harry Towbin
-
Patent number: 5858666Abstract: A transducer for detecting biomolecules comprises a bottom and a top unit. The bottom unit has a set of parallel electrically conductive transmission lines thereon and probes attached to selected locations along each transmission line for binding with the target molecule. The top unit has thereon a second set of parallel transmission lines transverse to those on the bottom unit. By applying AC signals sequentially to the two sets of transmission lines, each of the probe locations at the intersection of the two transmission lines can be addressed and the response of the probe in an unfilled detector location or a complex formed by the probe and the target in a filled detector location can be measured. If the target has been labelled, than the label at each of the locations may also be detected. The device can also be used for measuring binding constants between the probe and the target and concentrations of target solutions.Type: GrantFiled: August 29, 1996Date of Patent: January 12, 1999Assignees: Biotechnology Research and Development Corporation, The Penn State Research FoundationInventor: Paul S. Weiss
-
Patent number: 5858682Abstract: A monoclonal antibody which specifically binds with an E2A/pbx1 fusion epitope.Type: GrantFiled: August 2, 1996Date of Patent: January 12, 1999Assignee: PharmingenInventors: Stefan Gruenwald, Bi-Ching Sang, Craig Monell
-
Patent number: 5858681Abstract: The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin .beta.15 gene (SEQ ID NO: 1) and having the deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that enhanced transcripts (mRNA) and expression of the thymosin .beta.15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.Type: GrantFiled: June 17, 1996Date of Patent: January 12, 1999Assignee: Children's Medical CenterInventors: Bruce R. Zetter, Lere Bao
-
Patent number: 5856442Abstract: Transcripts of the major histocompatibility complex (MHC) Class I HLA-G gene which are present in foetal trophoblasts and/or in adult circulating mono-nuclear cells, as well as methods of using these. Either the said transcripts comprise, in succession in the 5' to 3' direction: a fragment encoding the signal peptide (exon 1), a fragment encoding the .alpha.1 domain (exon 2), a fragment encoding the .alpha.2 domain (exon 3), a fragment encoding the transmembrane TM domain (exon 5), a fragment encoding the cytoplasmic domain (exon 6) and the 3' untranslated fragment (exon 8), which sequence is designated HLA-G4, or the said transcripts comprise intron 4.Type: GrantFiled: March 17, 1995Date of Patent: January 5, 1999Assignee: Commissariat a l'Energie AtomiqueInventors: Edgardo Delfino Carosella, Philippe Moreau, Eliane Gluckman, Marek Kirszenbaum
-
Patent number: 5856106Abstract: Disclosed are a composition and method for determining the levels of specific immune responsiveness to a glycoprotein in an individual being treated therewith by (i) contacting a body fluid sample obtained from the individual prior to glycoprotein treatment with glycoprotein that has been modified to have an oxidized carbohydrate portion; (ii) contacting a body fluid sample obtained from the individual subsequent to glycoprotein treatment with the glycoprotein that has been modified to have an oxidized carbohydrate portion; and (iii) observing the degree of difference in the specific immune response to the oxidized glycoprotein in the pre- and post-treatment samples.Type: GrantFiled: November 1, 1995Date of Patent: January 5, 1999Assignee: BioTransplant, Inc.Inventors: Michel G. Awwad, Sonny Abraham, Mary E. White-Scharf, James A. Hope
-
Patent number: 5854000Abstract: Methods are disclosed for measuring the accumulation of advanced glycosylation endproducts (AGEs), which are predicated on the discovery that such AGEs are present in tobacco and its byproducts. More particularly, the methods focus on the observation that individuals who smoke or otherwise use tobacco have increased levels of AGEs over non-smoking individuals. The present methods relate to the measurement of AGE levels in both individuals and in tobacco and its byproduct, smoke. Methods are also disclosed for the evaluation of the tobacco products to determine their storage status and organoleptic capacity and potential, as well as for the treatment of the ambient to lower AGE levels. For example, air or other samples may be taken and evaluated by a dosimeter or like device, to determine whether AGE levels exceed normal, after which measures could be implemented to remediate the ambient condition. All such methods and corresponding materials are contemplated and included.Type: GrantFiled: March 18, 1996Date of Patent: December 29, 1998Assignees: Alteon Inc., The Picower Institute For Medical ResearchInventors: Richard J. Bucala, Helen Vlassara, Anthony Cerami, Henry W. Founds
-
Patent number: 5854009Abstract: Diagnostic/prognostic methods are provided for screening for pathologies wherein an alteration in estrogen metabolism is indicative of a pathology or a susceptibility thereto which comprise detecting and/or quantifying directly in tissues and body fluids of mammals abnormal levels of estrone metabolites and their glucuronide conjugates. Particularly preferred methods involve the use of the 16OHE1-, 2OHE1- or 2MeoE1-glucuronide fraction, i.e., the fraction which contains the metabolite and its 3-glucuronide conjugate. Methods of preparing reagents to detect said 16OHE1-, 2OHE1-, and 2MeoE1-glucuronide fraction in tissues and body fluids are disclosed as well as test kits for performing the disclosed assays.Type: GrantFiled: September 18, 1996Date of Patent: December 29, 1998Assignee: Immuna Care CorporationInventor: Thomas L. Klug
-
Patent number: 5851781Abstract: The present invention discloses novel immunogens, antibodies prepared from such immunogens, and labeled reagents useful in immunoassays for the detection and quantification of testosterone in a test sample. Also disclosed are immunoassays using these reagents and methods for synthesizing these reagents. The immunoassays are preferably microparticle enzyme immunoassays (MEIAs) and fluorescence polarization immunoassays (FPIAs). Further disclosed are novel starting materials for making the above novel immunogens and labeled reagents. Methods for making the novel immunogens and labeled reagents from the novel starting materials are also disclosed.Type: GrantFiled: April 28, 1995Date of Patent: December 22, 1998Assignee: Abbott LaboratoriesInventors: Maciej Adamczyk, Yon-Yih Chen, John A. Walling, Bryan D. James, Sharon G. Artrip
-
Patent number: 5851907Abstract: The present invention provides methods for separating ligands from binding proteins. The methods include acidic separation and size separation. The methods of the present invention are particularly useful for separating insulin-like growth factors from insulin-like growth factor binding proteins.Type: GrantFiled: February 23, 1996Date of Patent: December 22, 1998Inventors: Subburaman Mohan, David J. Baylink
-
Patent number: 5851778Abstract: A trifunctional conjugate is provided having three chemical moieties attached through a spacer moeity. At least two of the chemical moieties are relatively small molecules, usually less than about 7,000 Daltons in size. The spacer moiety is selected to impart certain steric properties to the conjugate. In one embodiment, the binding of a macromolecular specific binding partner to one of the chemical moieties sterically inhibits the binding of a different macromolecule to another chemical moiety. In another embodiment, the binding of a first chemical moiety to a macromolecule restricts the subsequent binding of a second chemical moiety to a proximate location on the same macromolecule. The three chemical moieties are preferably a nitrophenylazido residue, a phenyl boronic acid residue, and a solid support or a label such as biotin. The spacer is preferably cysteine, lysine, glutamic acid, pyroglutamic acid, S-acetylmercaptosuccinic anhydride or .omega.-carbobenzoxylysine.Type: GrantFiled: April 2, 1997Date of Patent: December 22, 1998Assignee: Beckman Instruments, Inc.Inventors: Chan S. Oh, James C. Sternberg
-
Patent number: 5851839Abstract: Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds.Type: GrantFiled: June 5, 1995Date of Patent: December 22, 1998Assignee: COR Therapeutics, Inc.Inventor: Robert M. Scarborough
-
Patent number: 5849480Abstract: A device for assaying haptens includes a solid support linked through a nucleic acid fragment to a reagent that can compete with the hapten for binding to antibodies that bind to the hapten. A process for assaying a hapten uses this device.Type: GrantFiled: March 16, 1995Date of Patent: December 15, 1998Assignee: Bio MerieuxInventors: Philippe Cros, Robin Kurfurst, Nicole Battail, Nadia Piga
-
Patent number: 5849495Abstract: A chemiluminescent assays for the determination of the presence or amount of a biopolymer in bound assays using 1,2-dioxetanes in connection with AttoPhos.TM. as chemiluminescent substrates for enzyme-labeled targets or probes is provided. Further disclosed is a kit for conducting a bioassay for the presence or concentration of a biopolymer comprising a) an enzyme complex; b) a 1,2-dioxetane; and c) AttoPhos.TM..Type: GrantFiled: March 4, 1997Date of Patent: December 15, 1998
-
Patent number: 5849507Abstract: Methods for diagnosing thrombosis are disclosed. The methods comprise contacting a biological fluid of a subject with an antibody which binds specifically to the peptide liberated when thrombin receptors are activated.Type: GrantFiled: June 7, 1995Date of Patent: December 15, 1998Assignee: The Regents of the University of CaliforniaInventor: Shaun R. Coughlin
-
Patent number: 5847088Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.Type: GrantFiled: June 7, 1995Date of Patent: December 8, 1998Assignee: ICOS CorporationInventors: Lawrence S. Cousens, Christine D. Eberhardt, Patrick Gray, Hai Le Trong, Larry W. Tjoelker, Cheryl L. Wilder